CN1883557A - Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression - Google Patents
Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression Download PDFInfo
- Publication number
- CN1883557A CN1883557A CNA2005100270868A CN200510027086A CN1883557A CN 1883557 A CN1883557 A CN 1883557A CN A2005100270868 A CNA2005100270868 A CN A2005100270868A CN 200510027086 A CN200510027086 A CN 200510027086A CN 1883557 A CN1883557 A CN 1883557A
- Authority
- CN
- China
- Prior art keywords
- group
- preparation
- model
- longgu
- gancao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 235000000434 Melocanna baccifera Nutrition 0.000 title description 43
- 241001497770 Melocanna baccifera Species 0.000 title description 43
- 239000000203 mixture Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 abstract description 30
- 230000002265 prevention Effects 0.000 abstract description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000237502 Ostreidae Species 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 34
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 31
- 230000035882 stress Effects 0.000 description 17
- 102400000739 Corticotropin Human genes 0.000 description 16
- 101800000414 Corticotropin Proteins 0.000 description 16
- 229960000258 corticotropin Drugs 0.000 description 16
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 16
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 15
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 15
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000003016 hypothalamus Anatomy 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 230000037328 acute stress Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 230000037326 chronic stress Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 235000014347 soups Nutrition 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 9
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000003390 Chinese drug Substances 0.000 description 7
- 206010062767 Hypophysitis Diseases 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000020401 Depressive disease Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000019082 Osmanthus Nutrition 0.000 description 5
- 241000333181 Osmanthus Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002180 anti-stress Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 241000202726 Bupleurum Species 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- 230000005622 photoelectricity Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 239000008539 xiaoyao Substances 0.000 description 3
- 244000205574 Acorus calamus Species 0.000 description 2
- 235000006480 Acorus calamus Nutrition 0.000 description 2
- 244000164480 Curcuma aromatica Species 0.000 description 2
- 235000003398 Curcuma aromatica Nutrition 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001673966 Magnolia officinalis Species 0.000 description 2
- 241001522129 Pinellia Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000012826 adjustment disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100168189 Rattus norvegicus Cort gene Proteins 0.000 description 1
- 101100329414 Rattus norvegicus Crh gene Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000013288 chronic stress animal model Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000021011 mixed nuts Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000013285 stress animal model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides the use of Chinese medicinal preparation of cinnamon twig, licorice root, dragon's bone and oyster in preparing medicament for the treatment and prevention of depression.
Description
Technical field:
The present invention relates to technical field of Chinese medicines.Be specifically related to the application of 'Guizhi Gancao Longgu Muli ' preparation in preparation control depression medicine.
Background technology:
Along with the fast development of social economy and science and technology, allegro work, life and fierce social competition, the pressure that the modern faces increases year by year.The modern disease that excessive psychentonia and maladjustment caused that current mental status with the people, socio-cultural background etc. cause, the sickness rate of difficult disease day by day increase.Various stress be with multi-form quality of life and the physical and mental health that affects people to some extent.Be the trend that rises year by year with sickness rate that stress diseases related in recent years.Persistence stress make the body's immunity disorder, and brings out and increase the weight of the generation of the multiple disease of body, as infectious disease, autoimmune disease, peptic ulcer, cardiovascular system, neural psychiatric system and tumor etc.Therefore, the unification of paying attention to body and mind with and lapse to the concern that effect in the back more more and more is subjected to medical circle at health and disease development, simultaneously, along with conversion of medical, explore and how to prevent and treat the focus that harm that excessive stress brings to body also becomes present research.
Stress (Stress) speech be physical term originally, the meaning is anxiety or pressure, think at present " biological stress be health to the nonspecific reaction of any requirement of being added on it ", the inharmonious state or the homeostasis that are body are on the hazard, and its principal character is that body is subjected to after internal and external environment stimulates hypophysis-adrenal cortex and sympathetic-adrenal medulla increased activity and excited, immunologic function disorder taking place.
Stress cause that anxiety and depression are generally acknowledged, studies show that the animal behavior activity of acute psychological phase increases, and the chronic psychological stress phase reduces, acute psychological shows as anxiety state, and chronic then is depressive state, and clinical manifestation is anxiety neurosis and depression.
Chinese medicine is having rich experience aspect the control depression.Depression belongs to the category of " strongly fragrant disease " " epilepsy " more, generally adopts compound recipe to treat, and its main method of treatment and square medicine are as follows:
1, depressed liver-energy dispersing and QI regulating method compound recipe commonly used has bupleurum powder for relieving liver-qi, strongly fragrant refreshing peace soup, XIAOYAO POWDER, Yueju Wan and some oneself plan side etc. disappear;
2, purging liver-fire method compound bupleurum root soup commonly used, pathogenic fire purging Ningxin soup etc.;
3, reduce phlegm depression-relief method compound recipe pinellia tuber and magnolia bark field commonly used, WEIDANTANG, Acorus calamus curcuma aromatica soup, forget excellent soup etc. according to one's conscience;
4, invigorating the heart and spleen method the kidney invigorating benefit commonly used god side, lilii and Rehmanniae Decoction, YIGUANJIAN;
The relative depression of the report of Chinese herb prevention anxiety neurosis will lack, and mainly contains: LIUWEI DIHUANG TANG, WEIDANTANG, some oneself side's of plan mixed nuts electuaries etc.
The Chinese medicine compound that has antidepressant and anxiety simultaneously has BANXIA HOUPU TANG, XIAOYAO POWDER.
The sweet LONGMU soup in Chinese medicine osmanthus comes from treatise on Febrile Diseases, is made up of Ramulus Cinnamomi, Os Draconis, Concha Ostreae, Radix Glycyrrhizae Preparata.The 384th of treatise on Febrile Diseases, " fire contrary, purgation, because of acupuncture with heated needle agitation person, 'Guizhi Gancao Longgu Muli ' preparation master it." so have invigorating the heart-YANG, effects of tranquilizing and allaying excitement cures mainly due to the deficiency of heart-YANG diseases such as dysphoria.
Based on above-mentioned effect, the sweet LONGMU soup in osmanthus mainly is used in the following aspects at present:
1, cardiac disorder: after one's own heart neurosis, arrhythmia
2, comprehensively card, depressive psychosis, insomnia, dizzy of climacteric
3, sweating syndrome
4, other: hyperthyroidism, septicopyemia blood disorder, gastric abscess, department of pediatrics night cry, frequent micturition, allergic rhinitis etc.
But do not have invigorating the heart-YANG so far, the sweet LONGMU soup in the osmanthus of tranquilizing effect changes the behavioristics that stress cause, comprises experiment and clinical report depressed and anxiety.
Summary of the invention:
Technical problem to be solved by this invention is the new application of the preparation that research design Chinese medicine Ramulus Cinnamomi, Radix Glycyrrhizae, Os Draconis, Concha Ostreae are formed.
The invention provides that Chinese medicine Ramulus Cinnamomi, Radix Glycyrrhizae, Os Draconis, Concha Ostreae forms the application of preparation in preparation control depression medicine.The preparation that the inventor forms Chinese medicine Ramulus Cinnamomi, Radix Glycyrrhizae, Os Draconis, Concha Ostreae has carried out the experiment of anti-stress effect to animal, and this experiment is as follows:
One, acute stress
(1) materials and methods
1 laboratory animal and grouping cleaning level SD rat, male and female half and half, body weight 180-220g, Chinese Academy of Sciences's Experimental Animal Center provides.The rat normal diet is 12h/12h in light-dark cycle, temperature (20 ± 2) ℃, adapt to 6 days in the environment of relative humidity 40% after, be divided into 7 groups at random by body weight, 13 of every treated animals: normal group, do not carry out the acute psychological modeling, gavage normal saline; Model I group gives the acute psychological modeling, does not gavage normal saline; Model II group gives the acute psychological modeling, gavages normal saline; 'Guizhi Gancao Longgu Muli ' preparation group gives the acute psychological modeling and gavages the 'Guizhi Gancao Longgu Muli ' preparation.
The composition and the dosage of 2 medicine Chinese medicine Ramulus Cinnamomi, Radix Glycyrrhizae, Os Draconis, Concha Ostreae preparation: Ramulus Cinnamomi 3g, Radix Glycyrrhizae 6g, Os Draconis 6g, Concha Ostreae 6g.All Chinese medicine is all available from Shanghai Hongqiao decoction pieces factory, and Pharmacy department's evaluation is pure Chinese crude drug, and water boiling concentration is to containing crude drug 1g/ml (dosage is 10 times of the every kg body weight of adult dosage) autoclaving, and 4 ℃ of refrigerators are preserved standby.
3 reagent and instrument acute stress animal model adopt the high voltage and constant current photoelectricity of neurobiology teaching and research room of The 2nd Army Medical College to stimulate instrument to carry out modeling, rat CRH, ACTH radioimmunological kit are provided by neurobiology teaching and research room of The 2nd Army Medical College, and rat CORT radioimmunological kit is provided by U.S. Diognostic Systems Laboratories.
4 experimental techniques
4.1 the making 'Guizhi Gancao Longgu Muli ' preparation group of medication and gross stress reaction model gavages Chinese medicine 2ml, every day 1 time, normal group and model II group gavage the normal saline of equivalent, gavage 19 days continuously.At the 18th day, 19 days, irritating stomach after 1 hour, all the other each groups all give electricity irritation except that normal group, make the gross stress reaction model: adopt high voltage and constant current photoelectricity to stimulate instrument to carry out electricity irritation, the electric pulse of the wide 2ms of ripple, per minute are once, intensity 1.4mA (constant current) lasts 20min.
4.3 test item and method
4.3.1 spacious experiment (Open-field test)
It is that black, bottom surface are divided into stroke in the cylindrical spacious case of 25 equal compositions of area that laboratory animal is placed high 40cm, diameter 80cm, perisporium, indoor sound insulation, record animal behavior, each minute 3min.To pass through the bottom surface block number is horizontal anomalous movement (Crossing) score, promptly strides into the number of times of adjacent lattice more than the three-jaw.(the 19th day) respectively survey was once before (the 11st day) and experiment finished before experiment, in the experiment.
4.3.2 tail hangs experiment
The position of rat tail end 1cm is fixed on (plank is apart from ground 1m) on the horizontal plank, makes animal present the reversal of the natural order of things shape.Hang both sides and separate the animal sight line with plank, observation index is 1. dead time, refers to that rat is in the accumulated time of loosening the transfixion state fully.2. struggle times refers to that rat is by the resupinate total degree of reversal of the natural order of things.(the 19th day) respectively survey was once before (the 11st day) and experiment finished before experiment, in the experiment
The back broken end is got blood 4.3.3 hypothalamus corticotropin releasing hormone (CRH), blood plasma thyroliberin (ACTH), serum corticosterone (CORT) rat are weighed, and preparation blood plasma, serum, cryopreservation are equipped with to be surveyed; The collection of rat hypothalamus body: rat broken end, cut open fast get cerebral tissue after, boil 5min rapidly in the normal saline that boils, the separation hypothalamus is weighed and is placed in the glass homogenate pipe, adds 1NHAC 1ml, fully be transferred in the plastic test tube after the homogenate, room temperature is placed 100min, and the centrifugal 20min of 4 ℃/4000rpm gets supernatant, be stored in-20 ℃ of refrigerators, to be measured.Hypothalamus CRH, plasma ACTH, serum corticosterone CORT are put the method for exempting from and are measured, and concrete steps are operated by the test kit requirement.
All experimental results of 5 statistical methods represent that with x ± s employing SPSS statistical software carries out variance analysis and compares in twos.
(2) experimental result
The influence that 1 'Guizhi Gancao Longgu Muli ' preparation is climbed the lattice number of times to spacious the experiment of acute stress rat is as shown in table 1, and before the experiment, gavaged Chinese medicine the 11st day, each group is climbed lattice number of times no significant difference (P＞0.05); Gavaging Chinese medicine the 19th day, modeling is compared with normal group two days later, model I group, and model II group is climbed lattice time number average significantly increases (P＜0.01); Compare with model I group, model II group, 'Guizhi Gancao Longgu Muli ' preparation group is climbed the lattice number of times, and there were significant differences (P＜0.01, P＜0.05).
Table 1 'Guizhi Gancao Longgu Muli ' preparation is climbed lattice number of times result (x ± s) to spacious the experiment of acute stress rat
| Group | The example number | Before the experiment | The 11st day | The 19th day |
| Climb the lattice number of times | Climb the lattice number of times | Climb the lattice number of times | ||
| Normal group | 13 | 48.54±6.53 | 49.69±10.18 | 50.69±11.86 |
| Model I group | 13 | 45.62±10.35 | 47.92±7.22 | 65.15±13.39 ** |
| Model II group | 13 | 47.69±10.3 | 53.08±10.52 | 68.38±7.82 ** |
| Ramulus Cinnamomi Radix Glycyrrhizae Os Draconis | 13 | 50.23±9.95 | 52.62±11.22 | 54.15±8.75 #△△ |
| Concha Ostreae preparation group |
Annotate: compare with normal group:
*P＜0.01, compare with model I group:
#P＜0.05, compare with model II group:
△ △P＜0.01
2 'Guizhi Gancao Longgu Muli ' preparations are as shown in table 2 to the influence of acute stress rat tail hanging test quiescent time, the experiment before, gavaged Chinese medicine the 11st day, each organizes no significant difference quiescent time (P＞0.05); Gavaging Chinese medicine the 19th day, modeling is compared with normal group two days later, model I group, and model II organizes and significantly shortens (P＜0.01) quiescent time; With model II group ratio, 'Guizhi Gancao Longgu Muli ' preparation group has significant prolongation (P＜0.05) quiescent time.
Table 2 'Guizhi Gancao Longgu Muli ' preparation is to acute stress rat tail hanging test quiescent time (x ± s) (unit: second)
| Group | The example number | Before the experiment | The 11st day | The 19th day |
| Quiescent time | Quiescent time | Quiescent time | ||
| Normal group | 13 | 222.77±38.61 | 206.46±40.85 | 206.31±38.66 |
| Model I group | 13 | 215.38±30.93 | 212.85±39.71 | 169.31±23.04 ** |
| Model II group | 13 | 217.77±42.34 | 207.77±34.73 | 157.69±31.5 ** |
| 'Guizhi Gancao Longgu Muli ' preparation group | 13 | 211.15±38.6 | 207.77±34.73 | 193.85±37.97 △ |
Annotate: compare with normal group:
*P＜0.01, compare with model II group:
△P＜0.05
3 'Guizhi Gancao Longgu Muli ' preparations are as shown in table 3 to the influence of acute stress rat tail hanging test struggle times, the experiment before, gavaged Chinese medicine the 11st day, each organizes struggle times no significant difference (P＞0.05), gavaging Chinese medicine the 19th day, modeling two days later, compare with normal group, model I group, model II group struggle times all significantly increases (P＜0.01); Compare with model I group, model II group, 'Guizhi Gancao Longgu Muli ' preparation group struggle times has remarkable minimizing (P＜0.01).
Table 3 'Guizhi Gancao Longgu Muli ' preparation is struggled to acute stress rat tail hanging test
The number of times result (x ± s)
| Group | The example number | Before the experiment | The 11st day | The 19th day |
| Struggle times | Struggle times | Struggle times | ||
| Normal group | 13 | 87.38±27.30 | 88.38±19.29 | 90.23±16.78 |
| Model I group | 13 | 81.62±25.63 | 83.62±20.06 | 126.08±24.66 ** |
| Model II group | 13 | 83.38±18.54 | 86.77±14.11 | 133.69±20.42 ** |
| Ramulus Cinnamomi Radix Glycyrrhizae Os Draconis | 13 | 78.62±18.94 | 79.85±16.67 | 98.23±16.65 ##△△ |
| Concha Ostreae preparation group |
Annotate: compare with normal group:
*P＜0.01, compare with model I group:
##P＜0.01, compare with model II group:
△ △P＜0.01
4 'Guizhi Gancao Longgu Muli ' preparations are as shown in table 4 to the influence of acute stress rat hypothalamus CRH, plasma ACTH and change of serum C ORT content, compare with normal group, two model group rat hypothalamus CRH, plasma ACTH and change of serum C ORT content all obviously increase (P＜0.01, P＜0.05); Compare with model I group, 'Guizhi Gancao Longgu Muli ' preparation group CRH, CORT content significantly reduce (P＜0.05); Compare with model II group, 'Guizhi Gancao Longgu Muli ' preparation group CRH, ACTH, CORT significantly reduce (P＜0.01, P＜0.05).
Table 4 'Guizhi Gancao Longgu Muli ' preparation to acute stress rat hypothalamus CRH,
Plasma ACTH and change of serum C ORT content content results
| Group | The example number | Hypothalamus CRH (pg/mg) | Plasma ACTH (pg/ml) | Serum corticosterone (ng/ml) |
| Normal group | 11 | 26.72±7.10 | 22.45±4.82 | 215.20±235.59 |
| Model I group | 11 | 36.37±9.05 * | 26.59±5.29 ** | 536.56±291.69 ** |
| Model II group | 11 | 39.47±10.83 ** | 28.92±4.14 ** | 582.16±311.58 ** |
| 'Guizhi Gancao Longgu Muli ' preparation group | 11 | 27.18±7.61 #△△ | 24.88±4.38 △ | 296.22±263.98 #△△ |
Annotate: compare with normal group:
*P＜0.05
*P＜0.01, compare with model I group:
#P＜0.05, compare with model II group:
△P＜0.05
△ △P＜0.01
Two, chronic stress
Chronic stress is the modeling method difference, and other material, test item are the same with acute stress with method.
Chronic stress modeling method and medication are: 'Guizhi Gancao Longgu Muli ' preparation group gavages Chinese medicine 2ml, and every day 1 time, normal group and model II group gavage the normal saline of equivalent, gavage 19 days continuously.Irritating stomach after 1 hour every day, and all the other each groups all give electricity irritation except that normal group, make the chronic stress reaction model: adopt high voltage and constant current photoelectricity stimulation instrument to carry out electricity irritation, the electric pulse of the wide 2ms of ripple, per minute once, intensity 1.0mA (constant current) lasts 20min.
Experimental result
The influence that 1 'Guizhi Gancao Longgu Muli ' preparation is climbed the lattice number of times to spacious experiment of chronic stress rat is as shown in table 5, and each group is climbed lattice number of times no significant difference (P＞0.05) before the experiment; Modeling the 11st day is compared with normal group, and model I group, model II group are climbed lattice time number average and significantly reduced (P＜0.01); Modeling the 19th day, to compare with normal group, model I group, model II group are climbed lattice time number average and are significantly reduced (P＜0.01), compare with model I group, model II group, and Os Draconis Concha Ostreae preparation group is climbed the lattice number of times remarkable rising (P＜0.01, P＜0.05).
Table 5 'Guizhi Gancao Longgu Muli ' preparation is climbed lattice number of times knot to spacious experiment of chronic stress rat
Really (x ± s)
| Group | The example number | Before the experiment | The 11st day | The 19th day |
| Climb the lattice number of times | Climb the lattice number of times | Climb the lattice number of times | ||
| Normal group | 13 | 74.31±23.93 | 62.23±29.28 | 60.08±30.46 |
| Model I group | 13 | 85.69±18.04 | 38.15±16.46 ** | 24.00±13.01 ** |
| Model II group | 13 | 77.00±23.97 | 30.15±14.00 ** | 18.92±11.40 ** |
| 'Guizhi Gancao Longgu Muli ' preparation group | 13 | 81.23±20.89 . | 40.92±15.87 | 41.08±17.96 #△△ |
Annotate: compare with normal group:
*P＜0.01, compare with model I group:
#P＜0.05, compare with model II group:
△ △P＜0.01
2 'Guizhi Gancao Longgu Muli ' preparations are as shown in table 6 to the influence of chronic stress rat tail hanging test quiescent time, and before the experiment, each organizes no significant difference quiescent time (P＞0.05); Modeling the 11st day is compared with normal group, model I group, and model II organizes does not all have significant difference (P＞0.05) quiescent time; Modeling the 19th day, compare model I group, all significantly (P＜0.05) prolongations quiescent time of model II group with normal group; Organize ratio with model I group, model II, 'Guizhi Gancao Longgu Muli ' preparation group has remarkable shortening (P＜0.05) quiescent time.
Table 6 'Guizhi Gancao Longgu Muli ' preparation is to chronic stress rat tail hanging test knot quiescent time
Really (x ± s) (unit: second)
| Group | The example number | Before the experiment | The 11st day | The 19th day |
| Quiescent time | Quiescent time | Quiescent time | ||
| Normal group | 13 | 217.69±43.82 | 176.38±56.40 | 160.89±48.59 |
| Model I group | 13 | 218.92±48.68 | 207.03±41.39 | 207.10±53.19 * |
| Model II group | 13 | 223.15±36.07 | 167.23±43.97 | 211.67±37.76 * |
| 'Guizhi Gancao Longgu Muli ' preparation group | 13 | 204.80±42.96 | 138.95±65.11 | 162.35±68.40 #△ |
Annotate: compare with normal group:
*P＜0.05, compare with model I group:
#P＜0.05, compare with model II group:
△P＜0.05
3 'Guizhi Gancao Longgu Muli ' preparations are as shown in table 7 to the influence of chronic stress rat tail hanging test struggle times, respectively organize struggle times no significant difference (P＞0.05) before the experiment; Modeling the 11st day is compared with normal group, and model II group struggle times has remarkable minimizing (P＜0.05); Modeling the 19th day is compared with normal group, and model I group is though model II group struggle times has minimizing trend, can there is not statistical significance (P＞0.05).
Table 7 'Guizhi Gancao Longgu Muli ' preparation is struggled inferior to chronic stress rat tail hanging test
The number result (x ± s)
| Group | The example number | Before the experiment | The 11st day | The 19th day |
| Struggle times | Struggle times | Struggle times | ||
| Normal group | 13 | 69.77±23.15 | 55.69±29.75 | 68.00±38.01 |
| Model I group | 13 | 71.85±18.07 | 44.77±17.95 | 62.38±30.73 |
| Model II group | 13 | 69.38±12.84 | 37.69±18.35 * | 43.38±22.24 |
| 'Guizhi Gancao Longgu Muli ' preparation group | 13 | 66.08±20.48 | 50.92±14.85 | 63.15±26.27 |
Annotate: compare with normal group:
*P＜0.05
4 'Guizhi Gancao Longgu Muli ' preparations are as shown in table 8 to the influence of chronic stress rat hypothalamus CRH, plasma ACTH and change of serum C ORT content, compare with normal group, two model group rat hypothalamus CRH, plasma ACTH and change of serum C ORT content all obviously increase (P＜0.01, P＜0.05); Compare with model I group, 'Guizhi Gancao Longgu Muli ' preparation group ACTH content significantly reduces (P＜0.01); Compare 'Guizhi Gancao Longgu Muli ' preparation group ACTH, CORT significant difference (P＜0.01, P＜0.05) with model II group.
Table 8 'Guizhi Gancao Longgu Muli ' preparation to chronic stress rat hypothalamus CRH,
Plasma ACTH and change of serum C ORT content results
| Group | The example number | Hypothalamus CRH (pg/mg) | Plasma ACTH (pg/ml) | Serum corticosterone (ng/ml) |
| Normal group | 11 | 23.83±6.38 | 31.83±3.34 | 480.94±254.13 |
| Model I group | 11 | 30.86±7.51 * | 37.51±2.22 ** | 642.10±214.75 |
| Model II group | 11 | 33.91±10.37 ** | 42.36±5.17 ** | 729.08±210.61 * |
| 'Guizhi Gancao Longgu Muli ' preparation group | 11 | 27.47±7.85 | 31.17±2.34 ##△△ | 481.58±233.42 △ |
Annotate: compare with normal group:
*P＜0.05
*P＜0.01, compare with model I group:
##P＜0.01, compare with model II group:
△P＜0.05
△ △P＜0.01
Three, analysis and conclusion
This experiment is mainly observed the action effect of 'Guizhi Gancao Longgu Muli ' preparation to the acute and chronic stress animal model with ethological change, hypothalamus-hypophysis-adrenal variation.It is main according to being:
In stress, hypothalamus-hypophysis-adrenal gland (HPA) axle has played critical effect, and a pattern that nerve information is converted to physiological reaction is provided.During the physical stress reaction, the cognitive process of central nervous system's high-level center causes some releasing factors (releasing factor), as corticotropin releasing hormone (CRH), in hypothalamus is released into Portal circulation between hypothalamus and the pituitary gland, thereby cause the release of hypophysis ACTH, ACTH remakes and is used for the adrenal gland, causes the synthetic of glucocorticoid and discharges.It is generally acknowledged, stress cause that the activity of hypothalamus hypophysis hypothalamic pituitary adrenal axis strengthens, play a role, thereby cause the change of a series of metabolism and function by glucocorticoid.These behaviors change and mainly contain: vigilance and vigilant the raising, and attention is concentrated and adaptability to changes strengthens, and is glad or dejected, and vegetative nerve function such as appetite, the inhibition of ingesting etc.; Physiological change be mainly reflected in oxygen for and the reallocation of nutrient substance, in addition, heart beating and breathe all and accelerate, glyconeogenesis and steatolysis strengthen, Detoxication also is improved, and on the contrary, grows and aspect such as reproduction is suppressed.
Spacious experiment is that comparatively classical reflection rat is in the exploratory behavior of new environment and the method for emotion, can be used to " excitement " or " depression " state of test animal central nervous system, the Mus tail hangs " disappointment " emotion and " depression " state that experiment also can reflect animal.Use the two in the pharmacological evaluation always and carry out the primary dcreening operation of antidepressant drug.
Studies show that, the animal behavior activity of acute psychological phase increases, and the chronic psychological stress phase reduces, acute psychological shows as anxiety state, chronic then is depressive state, this experimental observation hangs experiment rat behavior is observed by spacious experiment, tail, and the behavioral activity of animal increases after acute modeling, shows that animal stress still be in the acute stage anxiety state; The behavioral activity of animal reduces after chronic modeling, shows that animal shows as depressive state.
Above-mentioned experimental result shows, the 'Guizhi Gancao Longgu Muli ' preparation to acute and chronic stress behavior, hypothalamus-hypophysis-adrenal change all have-set the tone joint effect (the acute stress effect is more obvious), show that its effect that anti-stress is arranged reaches producing some relevant performances, as " anxiety ", " depression " etc. the improvement effect is arranged, can prevent and treat the harm that excessive stress brings to body.
The depression that 'Guizhi Gancao Longgu Muli ' preparation anti-stress causes and the new effectiveness of anxiety, significant in the research of preparation anti-stress Chinese medicine, there is wide economic benefit to be worth with theoretical.
The specific embodiment:
Embodiment 1, depressed 40 examples of 'Guizhi Gancao Longgu Muli ' soup therapeutic response
Reactive depression is satisfactory again because of depression of sex, by stressors effect onsets such as intensive direct stimulation or persistent psychentonia, clinical manifestation is a principal character with outstanding depressive emotion, also there are many-sided obstacles such as cognition, behavior and body regulatory function simultaneously, its symptom performance is easy to understand, and have tangible relatedly with the direct stimulation factor, the course of disease is changeable.
1 case is collected and treatment
The patient is from Shanghai Univ. of Traditional Chinese Medicine's Longhua hospital outpatient.40 routine patients, wherein male 23 examples, women 17 examples, 41.23 years old mean age (17-70 year).Meet the diagnosis of CCMD-3 reactive depression, be divided into Chinese drug-treated group 25 examples, Western medicine group 15 examples.
2 Therapeutic Method
Chinese drug-treated group: whole patients all take osmanthus sweet LONGMU Tonga and subtract treatment, basic side's medicine: Ramulus Cinnamomi 6g, Radix Glycyrrhizae 12g, Os Draconis 12g, Concha Ostreae 12g.The palpitation and insomnia person adds Caulis Polygoni Multiflori 12g, Semen Ziziphi Spinosae 12g; The weak person of the soreness of waist adds Cortex Eucommiae 12g, Radix Dipsaci 12g headache; Dizzy person adds Rhizoma Gastrodiae 12g, Ramulus Uncariae Cum Uncis 15g; The insufficiency of kidney-YANG person adds Rhizoma Curculiginis 10g, Herba Epimedii 12g partially; Hectic fever night sweat LONGMU adds to 30g, Fructus Tritici Levis 12g; The deficiency of the kidney yin person adds 12g Radix Ophiopogonis, Radix Rehmanniae 10g partially.1 dose of every day, with 15 days be a course of treatment, treat 3 courses of treatment.
The Western medicine group: initial 75mg/ day of imipramine, increase to gradually 150-200mg/ day after the week, maximum amount is no more than 250mg/ day.
3 statistical methods adopt the t check.Use SPSS10.0 statistical software deal with data.
4 efficacy evaluations
Before treatment by two doctors carry out simultaneously Hamilton depressive scale (Hamiltonratingscale for depression, HAMD), the scoring of the comprehensive grading scale (clinical global impressions.severity of illness scale.CGI.S) of clinical manifestation; After finishing, treatment also carries out simultaneously HAMD, the scoring of CGI.S again by above-mentioned two doctors.The branch rate that subtracts 〉=50% with HAMD and CGI-S serves as effective.
5 results
5.1 two groups of HAMD in treatment front and back and CGI.S scoring self relatively see Table 1.
Table one or two group is treated front and back HAMD and CGI.S marks relatively (x ± s)
| Group | n | HAMD | CGI.s | ||||
| Before the treatment | After the treatment | Subtract branch rate (%) | Before the treatment | After the treatment | Subtract branch rate (%) | ||
| Chinese drug-treated group | 25 | 20.97±6.3 | 9.62±5.2 * | 54.1 | 4.3±0.7 | 1.8±1.3 △ | 58.1 |
| The Western medicine group | 15 | 20.3±6.5 | 9.10±6.3 * | 55.1 | 4.2±0.6 | 1.7±1.2 δ | 59.5 |
Annotate: relatively preceding with treatment, * P＜0.01, △ P＜0.05
Two groups of variations for the treatment of front and back HAMD and CGI.S integration are compared, and difference has significance meaning (P＜0.05)
What two groups of curative effects were relatively treated HAMD that the back Chinese drug-treated group has 17 routine patients and CGI.S subtracts branch rate＞50%, and the treatment by Chinese herbs effective percentage is 68% (17/25); What the Western medicine group had HAMD behind the 11 routine patient treatments and a CGI.S subtracts branch rate＞50%, and the western medicine effective percentage is 73% (11/15), and two groups relatively, and difference does not have significance meaning (P＞0.05).
5.2 blood plasma 5-HT, NE odds ratio see Table 2 before and after two groups of treatments.
Blood plasma 5-HT, NE, 5-HT/NE odds ratio are before and after the table 2 liang group treatment
| Group | n | 5-HT(μg/L) | NE(μg/L) | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Chinese drug-treated group | 25 | 6.49±2.9 | 4.03±1.45 *△ | 5.97±3.12 | 11.97±6.43 * |
| The Western medicine group | 15 | 5.08±2.63 | 6.09±3.56 | 7.55±5.43 | 9.68±8.64 |
Annotate: relatively preceding with the treatment of this group, the back is treated relatively, △ P＜0.05 with the Western medicine group in * P＜0.01
Chinese drug-treated group treatment back blood plasma 5-HT concentration reduces, and NE concentration rises, and comparing difference all has significance (P＜0.01) before the treatment.Western medicine group treatment back 5-HT concentration and NE concentration rise, but do not have significance (P＞0.05) with the preceding comparing difference of treatment.Treatment back Chinese drug-treated group blood plasma 5-HT concentration is than Western medicine group low (P＜0.05) between two groups.
6 analyze and conclusion
Chinese medicine is having rich experience aspect the control depression.Depression belongs to " strongly fragrant disease " " epilepsy " more " category; generally adopt compound recipe to treat; its main method of treatment is depressed liver-energy dispersing and QI regulating, purging liver-fire, the dissipating depression of QI that reduces phlegm, invigorating the heart and spleen; compound recipe commonly used has bupleurum powder for relieving liver-qi, XIAOYAO POWDER, pinellia tuber and magnolia bark field, WEIDANTANG, Acorus calamus curcuma aromatica soup, the kidney invigorating benefit god side, lilii and Rehmanniae Decoction, YIGUANJIAN etc.; but not have invigorating the heart-YANG so far, the experiment and the clinical report of the osmanthus of tranquilizing effect sweet LONGMU soup therapeutic response depression.
Above-mentioned clinical and laboratory observation result has confirmed the antidepressant new effectiveness of 'Guizhi Gancao Longgu Muli ' preparation, and is significant in the research of preparation antidepressant Chinese medicine, has wide economic benefit to be worth with theoretical.
Embodiment 2, and Ramulus Cinnamomi 30kg, Radix Glycyrrhizae 60kg, Os Draconis 60kg, Concha Ostreae 60kg are made capsule; Ramulus Cinnamomi 14kg, Radix Glycyrrhizae 62kg, Os Draconis 62kg, Concha Ostreae 62kg make tablet; Ramulus Cinnamomi 60kg, Radix Glycyrrhizae 60kg, Os Draconis 60kg, Concha Ostreae 60kg make granule.Observational technique is treated involutional depression with embodiment 1, and effective percentage is 59%～70%.
Claims (2)
1, the application of a kind of Chinese medicine composition in preparation control depression medicine is characterized in that this Chinese medicine is made up of Ramulus Cinnamomi, Radix Glycyrrhizae, Os Draconis and Concha Ostreae.
2, require 1 described Chinese medicine composition according to the branch profit, it is characterized in that: Ramulus Cinnamomi account for the medicine total amount 5%～50%, Radix Glycyrrhizae account for the medicine total amount 10%～50%, Os Draconis account for the medicine total amount 10%～50%, Concha Ostreae accounts for 10%～50% of medicine total amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100270868A CN100394933C (en) | 2005-06-23 | 2005-06-23 | Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100270868A CN100394933C (en) | 2005-06-23 | 2005-06-23 | Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1883557A true CN1883557A (en) | 2006-12-27 |
| CN100394933C CN100394933C (en) | 2008-06-18 |
Family
ID=37581939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100270868A Expired - Fee Related CN100394933C (en) | 2005-06-23 | 2005-06-23 | Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100394933C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919924A (en) * | 2010-05-07 | 2010-12-22 | 广东药学院 | Pharmaceutical composition for curing tristimania and preparation method and application thereof |
| CN103599208A (en) * | 2013-11-16 | 2014-02-26 | 王纯治 | Traditional Chinese medicinal prescription for treating neurasthenia |
| CN104971095A (en) * | 2015-06-08 | 2015-10-14 | 吉林大学珠海学院 | Traditional Chinese medicine compound extractive with antidepressant activity and preparation method thereof |
| CN105942517A (en) * | 2016-07-16 | 2016-09-21 | 惠安县科联农业科技有限公司 | Anxiety-improving health-care food and preparing method thereof |
| CN113332314A (en) * | 2021-06-23 | 2021-09-03 | 广西云康健健康管理有限公司 | Oyster shell meat zymolyte and application thereof in preparation of medicines, foods or health-care products for preventing and treating depression |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1122517C (en) * | 2000-03-21 | 2003-10-01 | 刘立全 | 'Yuxianan' capsule |
-
2005
- 2005-06-23 CN CNB2005100270868A patent/CN100394933C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919924A (en) * | 2010-05-07 | 2010-12-22 | 广东药学院 | Pharmaceutical composition for curing tristimania and preparation method and application thereof |
| CN103599208A (en) * | 2013-11-16 | 2014-02-26 | 王纯治 | Traditional Chinese medicinal prescription for treating neurasthenia |
| CN103599208B (en) * | 2013-11-16 | 2015-10-28 | 王纯治 | One treats neurasthenic Chinese medicinal formulae |
| CN104971095A (en) * | 2015-06-08 | 2015-10-14 | 吉林大学珠海学院 | Traditional Chinese medicine compound extractive with antidepressant activity and preparation method thereof |
| CN104971095B (en) * | 2015-06-08 | 2019-07-19 | 吉林大学珠海学院 | A kind of Chinese medicinal compound extract and preparation method thereof with antidepressant activity |
| CN105942517A (en) * | 2016-07-16 | 2016-09-21 | 惠安县科联农业科技有限公司 | Anxiety-improving health-care food and preparing method thereof |
| CN113332314A (en) * | 2021-06-23 | 2021-09-03 | 广西云康健健康管理有限公司 | Oyster shell meat zymolyte and application thereof in preparation of medicines, foods or health-care products for preventing and treating depression |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100394933C (en) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1167454C (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN1872329A (en) | Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100394933C (en) | Application of 'Guizhi Gancao Longgu Muli' preparation in preparation of medicine for preventing and treating depression | |
| CN1561994A (en) | Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease | |
| CN1288748A (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
| CN1199656C (en) | Medicine for treating myashthenia gravis | |
| CN1733242A (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN1876144A (en) | A Chinese medicine for treating skin disease of fur-bearing animal and preparation process thereof | |
| CN1232698A (en) | Health beverage capable of tranquilizing through nourishing the heart | |
| CN1698804A (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN1112424A (en) | Toutongning-medicine for headache | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1872277A (en) | Application of medication composition of containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1294862A (en) | Canned rice gruel with functions of resisting fatigue, resisting oxygen deficit and regulating sleep | |
| CN1105869A (en) | Special Chinese-medicinal preparation for radically dropping drug | |
| CN1254263C (en) | Chinese medicine composition for treating senile dementia | |
| CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN1824075A (en) | Medicinal composition for treating hemicrania and its application | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN104740579B (en) | Premenstrual peace piece and its preparation technology | |
| CN1278734C (en) | Pharmaceutical composition for stopping drug addiction and its preparing process | |
| CN104435437B (en) | A kind ofly treat Chinese medicine of the concurrent glossopharyngeal neuralgia of trigeminal neuralgia and preparation method thereof | |
| CN102949656A (en) | Health care product capsule used for preventing and treating depression and preparation method thereof | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080618 Termination date: 20120623 |